Buchan Tayler A, Moayedi Yasbanoo, Truby Lauren K, Guyatt Gordon, Posada Juan Duero, Ross Heather J, Khush Kiran K, Alba Ana C, Foroutan Farid
Peter Munk Cardiac Center, Toronto General Hospital-University Health Network, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Ontario, Canada.
Peter Munk Cardiac Center, Toronto General Hospital-University Health Network, Ontario, Canada.
J Heart Lung Transplant. 2021 Jul;40(7):642-651. doi: 10.1016/j.healun.2021.03.015. Epub 2021 Mar 20.
Primary graft dysfunction (PGD) is a leading cause of early mortality after heart transplant (HTx). To identify PGD incidence and impact on mortality, and to elucidate risk factors for PGD, we systematically reviewed studies using the ISHLT 2014 Consensus Report definition and reporting the incidence of PGD in adult HTx recipients.
We conducted a systematic search in January 2020 including studies reporting the incidence of PGD in adult HTx recipients. We used a random effects model to pool the incidence of PGD among HTx recipients and, for each PGD severity, the mortality rate among those who developed PGD. For prognostic factors evaluated in ≥2 studies, we used random effects meta-analyses to pool the adjusted odds ratios for development of PGD. The GRADE framework informed our certainty in the evidence.
Of 148 publications identified, 36 observational studies proved eligible. With moderate certainty, we observed pooled incidences of 3.5%, 6.6%, 7.7%, and 1.6% and 1-year mortality rates of 15%, 21%, 41%, and 35% for mild, moderate, severe and isolated right ventricular-PGD, respectively. Donor factors (female sex, and undersized), recipient factors (creatinine, and pre-HTx use of amiodarone, and temporary or durable mechanical support), and prolonged ischemic time proved associated with PGD post-HTx.
Our review suggests that the incidence of PGD may be low but its risk of mortality high, increasing with PGD severity. Prognostic factors, including undersized donor, recipient use of amiodarone pre-HTx and recipient creatinine may guide future studies in exploring donor and/or recipient selection and risk mitigation strategies.
原发性移植功能障碍(PGD)是心脏移植(HTx)后早期死亡的主要原因。为了确定PGD的发生率及其对死亡率的影响,并阐明PGD的危险因素,我们系统回顾了采用国际心脏和肺移植学会(ISHLT)2014年共识报告定义并报告成年HTx受者中PGD发生率的研究。
我们于2020年1月进行了系统检索,纳入报告成年HTx受者中PGD发生率的研究。我们使用随机效应模型汇总HTx受者中PGD的发生率,并针对每种PGD严重程度,汇总发生PGD者的死亡率。对于在≥2项研究中评估的预后因素,我们使用随机效应荟萃分析汇总PGD发生的调整比值比。GRADE框架为我们评估证据的确定性提供了依据。
在检索到的148篇出版物中,36项观察性研究符合纳入标准。我们有中等程度的把握观察到,轻度、中度、重度和孤立性右心室PGD的汇总发生率分别为3.5%、6.6%、7.7%和1.6%,1年死亡率分别为15%、21%、41%和35%。供体因素(女性和供心过小)、受体因素(肌酐、HTx前使用胺碘酮以及临时或持久机械支持)和缺血时间延长被证明与HTx后PGD相关。
我们的综述表明,PGD的发生率可能较低,但其死亡风险较高,且随PGD严重程度增加而升高。包括供心过小、受体HTx前使用胺碘酮和受体肌酐在内的预后因素可能为未来探索供体和/或受体选择及风险降低策略的研究提供指导。